Poolbeg Pharma Ltd. (7JN) AI Stock Analysis

1 Followers

Poolbeg Pharma Ltd.

(Frankfurt:7JN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Debt-free balance sheetThe absence of reported debt limits interest obligations and reduces refinancing pressure while the company funds clinical development. This provides more balance-sheet flexibility than leveraged peers, although maintaining that advantage depends on managing ongoing cash consumption.

Negative Factors

Pre-revenue business modelThe absence of commercial revenue means Poolbeg currently lacks an operating income base to fund research and administration. Until a program is partnered on meaningful terms or reaches commercialization, financial performance remains dependent on development progress and external sources of capital.

Poolbeg Pharma Ltd. (7JN) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 44.66M
Dividend Yield: ―
Average Volume (3M): 2,914
Price to Earnings (P/E): -7.5
Beta (1Y): 0.60
Revenue Growth: ―
EPS Growth: 33.33%
Country: Germany
Employees: 15
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Poolbeg Pharma Ltd. Business Overview & Revenue Model

Company Description

Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for seve...

Poolbeg Pharma Ltd. Earnings Call Summary

Earnings Call Date:Apr 28, 2026(Q4-2025)|% Change Since:45.00%|Next Earnings Date:Mar 03, 2022

Earnings Call SentimentPositive

The call conveyed strong progress across regulatory, IP, preclinical/clinical readiness and partnership engagement, supported by concrete metrics (GBP 7.7m cash, GBP 4.865m fundraising, GBP 3.4m grant, Orphan Drug designation, patents, ~85%–95% cytokine inhibition in LPS model). Key upcoming inflection points (TOPICAL interim readout expected summer 2026; oral GLP-1 trial in H2 2026) underpin near-term value catalysts. Offset risks include a manufacturing delay for the GLP-1 program, a small open-label TOPICAL study requiring further confirmatory work, dependence on partners for late-stage development/commercialization, and a funding runway limited to 2027. On balance, highlights materially outweigh lowlights given the substantive regulatory milestones, strong early efficacy signals, payer interest and active partnering — suggesting positive momentum ahead of the summer data readout.

Positive Updates

Clinical Progress — TOPICAL (POLB 001) Ready to Start

MHRA approval obtained, protocol finalized, 6 UK sites secured (The Christie, UCH, Royal Marsden, Birmingham, NHS North Midlands/Royal Stoke, Edinburgh), ACT appointed as CRO, J&J supplying teclistamab at no cost, patient recruitment and dosing imminent for ~30 relapsed/refractory multiple myeloma patients.

Negative Updates

GLP-1 Program Manufacturing Delay

Start of the oral GLP-1 clinical trial deferred to the second half of 2026 due to revised manufacturing lead times, delaying the anticipated timeline for proof-of-concept readout.

Company Guidance

Management guided that Poolbeg has financial runway into 2027 (cash £7.7m at FY2025, following a £4.865m fundraising and with a £3.4m RISE grant), that the POLB‑001 TOPICAL CRS‑prevention trial is fully prepared (MHRA approval, ACT as CRO, J&J supplying teclistamab at no cost) and will enroll ~30 relapsed/refractory multiple myeloma patients across 6 U.K. sites with twice‑daily dosing around the 5–8 day step‑up teclistamab period (when ~96–100% of CRS occurs), with interim data expected in summer 2026; this builds on a Phase Ib LPS human challenge (30/70/150 mg BID) showing dose‑response and ~85–95% suppression of IL‑6/IL‑8 (p38 inhibition ~80–90%). They reiterated a >$10bn U.S./EU5 market opportunity (modeled from ~500,000 patients 2023–2030 and an illustrative ~$20,000 price point vs Neulasta’s ~$18,000), noted >70% CRS incidence with some T‑cell engagers, Grade‑3 CRS management costs >$70,000, patent coverage to at least 2044, and that an oral GLP‑1 PK/safety study in 20 volunteers is planned for H2 2026.

Poolbeg Pharma Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:7JN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:HVO	47Neutral	GBP 34.76M	-2.81	-35.13%	3.96%	-24.24%	-329.49%
GB:SAR	47Neutral	GBP 23.75M	-6.04	-188.01%	―	―	28.78%
GB:APTA	46Neutral	GBP 12.66M	-12.17	-46.61%	―	28.35%	57.14%
GB:HEMO	46Neutral	GBP 46.90M	-3.76	-409.57%	―	―	18.57%
GB:IMM	37Underperform	GBP 17.59M	-2.25	-559.87%	―	―	5.62%

* Healthcare Sector Average

Performance Comparison

DE:7JN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:7JN	Poolbeg Pharma Ltd.	0.06	0.02	65.71%
GB:IMM	ImmuPharma plc	2.82	-7.16	-71.74%
GB:SAR	Sareum Holdings	14.50	0.75	5.45%
GB:HEMO	Hemogenyx Pharmaceuticals Plc	680.00	-204.00	-23.08%
GB:HVO	Open Orphan Plc	5.05	-1.25	-19.84%
GB:APTA	Aptamer Group Plc	0.36	-0.57	-60.75%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Poolbeg Pharma Ltd. AI Stock Analysis